Literature DB >> 17536202

Treatment of epileptogenic cavernomas: surgery versus radiosurgery.

Peng-Wei Hsu1, Cheng-Nen Chang, Chen-Kan Tseng, Kuo-Cheng Wei, Chun-Chieh Wang, Chi-Cheng Chuang, Yin-Cheng Huang.   

Abstract

BACKGROUND: Epilepsy is the most common symptom of cavernoma. Although microsurgery is the mainstay treatment for epileptogenic cavernoma, this procedure may cause severe complications for some lesions. This report aimed to study if linear accelerator (LINAC) radiosurgery was an alternative treatment modality for epileptogenic cavernoma.
METHODS: In this retrospective study, 29 patients were diagnosed with epileptogenic cavernomas from September 1995 to March 2005. Fifteen patients were treated with surgical excision and 14 with LINAC radiosurgery. The evaluation of epilepsy control was according to Engel's classification.
RESULTS: In the surgical group, 13 (86.7%) of 15 patients had a class I seizure-free outcome. In the radiosurgery group, class I control was achieved in 9 (64.3%) of 14 patients. However, there was no significant difference in the results of treatment between the two groups.
CONCLUSIONS: LINAC radiosurgery is an alternative treatment for epileptogenic cavernomas, especially when the lesions are located in the central regions or eloquent areas of the brain.

Entities:  

Mesh:

Year:  2007        PMID: 17536202     DOI: 10.1159/000103126

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  2 in total

1.  Safety and effectiveness of stereotactic laser ablation for epileptogenic cerebral cavernous malformations.

Authors:  Jon T Willie; James G Malcolm; Matthew A Stern; Lindsay O Lowder; Stewart G Neill; Brian T Cabaniss; Daniel L Drane; Robert E Gross
Journal:  Epilepsia       Date:  2019-01-17       Impact factor: 5.864

2.  Magnetic Resonance Thermometry-Guided Stereotactic Laser Ablation of Cavernous Malformations in Drug-Resistant Epilepsy: Imaging and Clinical Results.

Authors:  D Jay McCracken; Jon T Willie; Brad A Fernald; Amit M Saindane; Daniel L Drane; Daniel L Barrow; Robert E Gross
Journal:  Oper Neurosurg (Hagerstown)       Date:  2015-09-25       Impact factor: 2.703

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.